Effect of food on capsule and granule formulations of selumetinib

• Autors principals: Sarit Cohen‐Rabbie (Autor), Alexandra Mattinson (Autor), Karen So (Autor), Nan Wang (Autor), Ronald Goldwater (Autor)
• Format: Llibre
• Publicat: Wiley, 2022-04-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Abstract Selumetinib is an oral, potent, and highly selective allosteric MEK1/2 inhibitor approved for the treatment of pediatric patients (aged ≥2 years) with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. A granule formulation of selumetinib is under development...